Live Quote · NYSEMYOVHealthcare· Biotechnology

Myovant Sciences Ltd.

$26.98 0.04%($-0.01)
TickerSpark Score
77/100
Solid
60
Valuation
65
Profitability
95
Growth
64
Health
100
Momentum

Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a MYOV research report →

52-Week Range100% of range
Low
$7.67
Current
$26.98
High
$27.06
Company Overviewmyovant.com

About the company

Myovant Sciences Ltd. is a biopharmaceutical company focused on innovating healthcare solutions for both women and men. Its flagship product is relugolix, an orally administered, once-daily small molecule that functions as a gonadotropin-releasing hormone (GnRH) receptor antagonist.

CEO
David C. Marek
IPO
2016
Employees
579
HQ
London, GB

Price Chart

+118.99% · this period
$27.02$17.40$7.78Mar 09Sep 08Mar 09
Valuation
Market Cap
$2.62B
P/E
-12.15
P/S
11.36
P/B
-5.30
EV/EBITDA
-14.06
Div Yield
0.00%
Profitability
Gross Margin
77.68%
Op Margin
-81.11%
Net Margin
-89.18%
ROE
49.79%
ROIC
-68.92%
Growth & Income
Revenue
$230.97M · 289.39%
Net Income
$-205,981,000 · 19.27%
EPS
$-2.22 · 21.55%
Op Income
$-187,346,000
FCF YoY
-173.07%
Performance & Tape
52W High
$27.06
52W Low
$7.67
50D MA
$26.92
200D MA
$21.54
Beta
2.15
Avg Volume
1.09M

Get TickerSpark's AI analysis on MYOV

Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.

Get Pro Access →

Already have an account? Log in

Form 4 · Filings

Recent insider transactions

Who's buying, who's selling, and how much.

DateInsiderTypeShares
Mar 10, 23Valente Nancysell3,673
Mar 10, 23Valente Nancysell36,892
Mar 10, 23POTTER MYRTLE Ssell58,608
Mar 10, 23POTTER MYRTLE Ssell21,603
Mar 10, 23POTTER MYRTLE Ssell3,673
Mar 10, 23POTTER MYRTLE Ssell21,096
Mar 10, 23POTTER MYRTLE Ssell45,000
Mar 10, 23Merendino Laurensell21,791
Mar 10, 23Merendino Laurensell147,747
Mar 10, 23Merendino Laurensell123,300
Coverage · MYOV

Our MYOV coverage

Recent articles, reports, and earnings notes.

On-Demand Research

No research on MYOV yet

For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.

Generate MYOV report →
Internal Compare

Similar companies

Peers in the same neighborhood.